These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 20170207)

  • 21. PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 3: comparative assessement of prediction methods of human clearance.
    Ring BJ; Chien JY; Adkison KK; Jones HM; Rowland M; Jones RD; Yates JW; Ku MS; Gibson CR; He H; Vuppugalla R; Marathe P; Fischer V; Dutta S; Sinha VK; Björnsson T; Lavé T; Poulin P
    J Pharm Sci; 2011 Oct; 100(10):4090-110. PubMed ID: 21541938
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Changes in cytochrome P450s-mediated drug clearance in patients with hepatocellular carcinoma in vitro and in vivo: a bottom-up approach.
    Gao J; Zhou J; He XP; Zhang YF; Gao N; Tian X; Fang Y; Wen Q; Jia LJ; Jin H; Qiao HL
    Oncotarget; 2016 May; 7(19):28612-23. PubMed ID: 27086920
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Toward a new paradigm for the efficient in vitro-in vivo extrapolation of metabolic clearance in humans from hepatocyte data.
    Poulin P; Haddad S
    J Pharm Sci; 2013 Sep; 102(9):3239-51. PubMed ID: 23494893
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Simcyp population-based ADME simulator.
    Jamei M; Marciniak S; Feng K; Barnett A; Tucker G; Rostami-Hodjegan A
    Expert Opin Drug Metab Toxicol; 2009 Feb; 5(2):211-23. PubMed ID: 19199378
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preterm Physiologically Based Pharmacokinetic Model. Part II: Applications of the Model to Predict Drug Pharmacokinetics in the Preterm Population.
    Abduljalil K; Pan X; Pansari A; Jamei M; Johnson TN
    Clin Pharmacokinet; 2020 Apr; 59(4):501-518. PubMed ID: 31587145
    [TBL] [Abstract][Full Text] [Related]  

  • 26. IMI - Oral biopharmaceutics tools project - Evaluation of bottom-up PBPK prediction success part 4: Prediction accuracy and software comparisons with improved data and modelling strategies.
    Ahmad A; Pepin X; Aarons L; Wang Y; Darwich AS; Wood JM; Tannergren C; Karlsson E; Patterson C; Thörn H; Ruston L; Mattinson A; Carlert S; Berg S; Murphy D; Engman H; Laru J; Barker R; Flanagan T; Abrahamsson B; Budhdeo S; Franek F; Moir A; Hanisch G; Pathak SM; Turner D; Jamei M; Brown J; Good D; Vaidhyanathan S; Jackson C; Nicolas O; Beilles S; Nguefack JF; Louit G; Henrion L; Ollier C; Boulu L; Xu C; Heimbach T; Ren X; Lin W; Nguyen-Trung AT; Zhang J; He H; Wu F; Bolger MB; Mullin JM; van Osdol B; Szeto K; Korjamo T; Pappinen S; Tuunainen J; Zhu W; Xia B; Daublain P; Wong S; Varma MVS; Modi S; Schäfer KJ; Schmid K; Lloyd R; Patel A; Tistaert C; Bevernage J; Nguyen MA; Lindley D; Carr R; Rostami-Hodjegan A
    Eur J Pharm Biopharm; 2020 Nov; 156():50-63. PubMed ID: 32805361
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Physiology-based simulations of a pathological condition: prediction of pharmacokinetics in patients with liver cirrhosis.
    Edginton AN; Willmann S
    Clin Pharmacokinet; 2008; 47(11):743-52. PubMed ID: 18840029
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Age-related changes of hepatic clearances of cytochrome P450 probes, midazolam and R-/S-warfarin in combination with caffeine, omeprazole and metoprolol in cynomolgus monkeys using in vitro-in vivo correlation.
    Koyanagi T; Nakanishi Y; Murayama N; Yamaura Y; Ikeda K; Yano K; Uehara S; Utoh M; Kim S; Uno Y; Yamazaki H
    Xenobiotica; 2015 Apr; 45(4):312-21. PubMed ID: 25364857
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Omeprazole drug interaction studies.
    Andersson T
    Clin Pharmacokinet; 1991 Sep; 21(3):195-212. PubMed ID: 1764870
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Physiologically Based Pharmacokinetic Model for Pregnant Women to Predict the Pharmacokinetics of Drugs Metabolized Via Several Enzymatic Pathways.
    Dallmann A; Ince I; Coboeken K; Eissing T; Hempel G
    Clin Pharmacokinet; 2018 Jun; 57(6):749-768. PubMed ID: 28924743
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hepatic and intestinal cytochrome P450 3A activity in cirrhosis: effects of transjugular intrahepatic portosystemic shunts.
    Chalasani N; Gorski JC; Patel NH; Hall SD; Galinsky RE
    Hepatology; 2001 Dec; 34(6):1103-8. PubMed ID: 11731998
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interplay of metabolism and transport in determining oral drug absorption and gut wall metabolism: a simulation assessment using the "Advanced Dissolution, Absorption, Metabolism (ADAM)" model.
    Darwich AS; Neuhoff S; Jamei M; Rostami-Hodjegan A
    Curr Drug Metab; 2010 Nov; 11(9):716-29. PubMed ID: 21189140
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prediction of in vivo drug clearance from in vitro data. I: impact of inter-individual variability.
    Howgate EM; Rowland Yeo K; Proctor NJ; Tucker GT; Rostami-Hodjegan A
    Xenobiotica; 2006 Jun; 36(6):473-97. PubMed ID: 16769646
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A mechanistic pharmacokinetic model to assess modified oral drug bioavailability post bariatric surgery in morbidly obese patients: interplay between CYP3A gut wall metabolism, permeability and dissolution.
    Darwich AS; Pade D; Ammori BJ; Jamei M; Ashcroft DM; Rostami-Hodjegan A
    J Pharm Pharmacol; 2012 Jul; 64(7):1008-24. PubMed ID: 22686346
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development and Evaluation of a Physiologically Based Pharmacokinetic Drug-Disease Model of Propranolol for Suggesting Model Informed Dosing in Liver Cirrhosis Patients.
    Kalam MN; Rasool MF; Alqahtani F; Imran I; Rehman AU; Ahmed N
    Drug Des Devel Ther; 2021; 15():1195-1211. PubMed ID: 33762817
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Assessment of cytochrome P450-mediated drug-drug interaction potential of orteronel and exposure changes in patients with renal impairment using physiologically based pharmacokinetic modeling and simulation.
    Lu C; Suri A; Shyu WC; Prakash S
    Biopharm Drug Dispos; 2014 Dec; 35(9):543-52. PubMed ID: 25264242
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fasting-Induced Changes in Hepatic P450 Mediated Drug Metabolism Are Largely Independent of the Constitutive Androstane Receptor CAR.
    de Vries EM; Lammers LA; Achterbergh R; Klümpen HJ; Mathot RA; Boelen A; Romijn JA
    PLoS One; 2016; 11(7):e0159552. PubMed ID: 27434302
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Extrapolation of the Hepatic Clearance of Drugs in the Absence of Albumin In Vitro to That in the Presence of Albumin In Vivo: Comparative Assessement of 2 Extrapolation Models Based on the Albumin-Mediated Hepatic Uptake Theory and Limitations and Mechanistic Insights.
    Poulin P; Haddad S
    J Pharm Sci; 2018 Jul; 107(7):1791-1797. PubMed ID: 29567347
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism.
    Thummel KE; O'Shea D; Paine MF; Shen DD; Kunze KL; Perkins JD; Wilkinson GR
    Clin Pharmacol Ther; 1996 May; 59(5):491-502. PubMed ID: 8646820
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prediction of hepatic clearance and availability by cryopreserved human hepatocytes: an application of serum incubation method.
    Shibata Y; Takahashi H; Chiba M; Ishii Y
    Drug Metab Dispos; 2002 Aug; 30(8):892-6. PubMed ID: 12124306
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.